Zydus Lifesciences announced that the safety and efficacy analysis data from the phase-III clinical trial of its Covid-19 vaccine ZyCoV-D has been examined and published in The Lancet, a reputed and well known medical journal.
The clinical trial of ZyCoV-D was one of the most significant trials for a Covid-19 vaccine in India. It was conducted on more than 28,000 adult volunteers at over 50 sites. The vaccine has shown good stability at a temperature of 25 degrees C for at least three months. The thermostability of the vaccine will help in easy transportation and storage of the vaccine and lower any cold chain breakdown challenges.

• Is your trading account keeping up with what markets demand in 2026?
• Texmaco Rail Surges 15% on Rs 4,045 Cr South African Rail Order
• RVNL Shares Gain 2% on Securing Rs 221 Crore Order 
• Tata Power Slides 3.85% as Q4 Profit Drops, Revenue Misses
• Stocks Under F&O Ban: Steel Authority of India

According to Zydus, the plug-and-play technology of the vaccine allows it to adapt to the SARS COV-2 virus. The trial was done during the peak of the second wave of the Covid-19 virus. The effectiveness of the vaccine stood at 66.6 per cent against the Delta Variant.